Emisphere Tech (EMIS) 0.6600 $EMIS Emisphere

New Post Public Reply Private Reply Replies (0) Message Board

Apr 12, 2015 at 8:49 AM

Emisphere Tech (EMIS) 0.6600 $EMIS

Emisphere Technologies' (EMIS) CEO Alan Rubino on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Mar 31, 10:15AM CDT

Emisphere Reports Fourth Quarter and Full Year 2014 Financial Results
GlobeNewswire - Tue Mar 31, 6:50AM CDT
Recent Launch of Eligen B12(TM) Marks Company's Expansion into Commercializing Practical Innovation

Emisphere Announces Fourth Quarter and Full Year 2014 Financial Results Conference Call
GlobeNewswire - Wed Mar 25, 3:20PM CDT
Emisphere Technologies, Inc. (OTCQB:EMIS) announced today that management will host a conference call on Tuesday, March 31, 2015, at 8:30 AM ET to discuss the Company's financial and operational results for the quarter and twelve months that ended December 31, 2014.

Key Aspects Of A Potential Novo Nordisk Oral GLP-1 Phase 3 Trial
PLM Investments - at Seeking Alpha - Fri Mar 20, 10:52AM CDT

NVO: 55.94 (+1.34)

Penny Stocks Alerts for Sabine Oil & Gas, HDS International, Integral Technologies, Quicksilver Resources, FLEXPOWER, and Emisphere
PR Newswire - Thu Mar 19, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Sabine Oil & Gas (OTCMKTS:SOGC), HDS International (OTCMKTS:HDSI), Integral Technologies (OTCMKTS:ITKG), Quicksilver Resources (OTCMKTS:KWKA), FLEXPOWER (OTCMKTS:FLXP), and Emisphere Technologies (OTCMKTS:EMIS).

Emisphere Launches Eligen B12(TM), the First Oral Prescription Tablet Proven to Normalize B12 Levels Without the Need for an Injection
PR Newswire - Thu Mar 19, 7:15AM CDT
Emisphere Technologies, Inc. (OTCBB: EMIS) today announced the U.S. commercial availability of Eligen B12(TM), the first and only once-daily oral prescription medical food tablet shown to normalize B12 levels without the need for an injection. Eligen B12 is indicated for the dietary management of patients who have a medically-diagnosed vitamin B12 deficiency, associated with a disease or condition that cannot be managed by a modification of the normal diet alone.

Novo Nordisk Is In The NASH Space, Too
PLM Investments - at Seeking Alpha - Wed Mar 18, 6:52PM CDT

NVO: 55.94 (+1.34), GILD: 101.77 (+0.61), ICPT: 279.25 (+7.48)

Novo-Nordisk's Oral GLP-1 Diabetes Treatment: An Update
PLM Investments - at Seeking Alpha - Thu Feb 19, 10:25AM CST

NVO: 55.94 (+1.34)

Emis Group's (EMIS) CEO Alan Rubino on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 14, 1:25PM CST

Emisphere Tech Q3 results
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 11:13AM CST

Emisphere Technologies EPS of -$0.24
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 7:36AM CST

Emisphere Technologies Announces Financial Results for the Third Quarter 2014
GlobeNewswire - Fri Nov 14, 7:00AM CST
Emisphere Technologies, Inc. (OTCBB:EMIS) ("Emisphere" or the "Company"

today announced its financial results for the quarter ended September 30, 2014. The Company will host a conference call this morning at 8:30 AM ET to discuss these results.

Emisphere reports November 14
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 8:34AM CST

Emisphere Technologies Announces Third Quarter 2014 Earnings Conference Call
GlobeNewswire - Wed Nov 12, 7:00AM CST
Emisphere Technologies, Inc. (OTCQB:EMIS) (the "Company"

announced today that Management will host a conference call to discuss the Company's financial and operational results for the three months ended September 30, 2014 on Friday, November 14, 2014 at 8:30 AM ET. A press release will be issued prior to market opening.

Emisphere enters into USD20m debt financing to introduce oral Eligen B12 in the US market
M2 - Thu Aug 21, 7:31AM CDT
Pharmaceutical company Emisphere Technologies (OTC BB:EMIS) reported on Wednesday the execution of new loan facility agreement to finance the upcoming launch of its first commercial prescription product oral Eligen B12 in the US for B12 deficient individuals.

Emisphere Announces $20 Million Debt Financing to Launch Oral Eligen(R) B12
GlobeNewswire - Wed Aug 20, 8:29AM CDT
Emisphere Technologies, Inc. (OTCBB:EMIS) ("Emisphere" or the "Company"

today announced that it has reached agreement with MHR Fund Management LLC, and certain of its affiliated funds ("MHR"

, to finance the upcoming launch of the Company's first commercial prescription product, oral Eligen B12 in the United States through a new loan facility, and to amend the terms of the Company's existing obligations under various promissory notes previously issued to MHR to extend the maturity dates of such promissory notes.

Competitor Analysis: GLP-1 Receptor Agonists Development Pipeline Report 2014
M2 - Tue Aug 19, 9:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7d4zkt/competitor) has announced the addition of the "Competitor Analysis: GLP-1 Receptor Agonists" report to their offering. The Competitive Intelligence Report Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists as of August 2014 provides a competitor analysis in the development pipeline of novel GLP-1 analogs and GLP-1 receptor agonists and co-agonists for treatment of diabetes and obesity. In the year 2013, the marketed daily and weekly GLP-1 agonists achieved combined sales of US$ 3,231 mln representing 6.3% of the total diabetes care market. The leading GLP-1 analog Victoza held 69% of the GLP-1 market and is further expanding its predominance in the first half of 2014 with a 72% share of the GLP-1 market which grew to 6.9% of the total diabetes care market. The increasingly attractive GLP-1 market provides an opportunity of application of new technologies to prolong the half-life of GLP-1 analogs as well as finding co-agonists of GLP-1 receptor with additional receptors, such as insulin, glucagon, GIP, gastrin or GLP-1. In addition, expansion of indications for GLP-1 analogs will contribute to further expand the GLP-1 market. The report provides a compilation of current active projects in research and development of novel GLP-1 analogs and GLP-1 receptor agonists as well as co-agonists. Competitor projects are listed in a tabular format providing information on: - Drug Codes - Target / Mechanism of Action - Class of Compound - Company - Product Category - Indication - R&D Stage - Additional comments with a hyperlink leading to the source of information. Key Topics Covered: 1. Selective GLP-1 Analogs for Metabolic Diseases - 2013 Sales of GLP-1 Analogs - Short-Acting Injectable GLP-1 Analogs - Long-Acting Injectable GLP-1 Analogs - Very Long-Acting Injectable GLP-1 Analogs - Oral Peptide-Based GLP-1 Analogs - Other Non-Injectable Peptide-Based GLP-1 Analogs - Oral Small Molecule GLP-1 Receptor Agonists 2. Selective GLP-1 Analogs for Non-Metabolic Diseases 3. Dual Target GLP-1 Analogs - GLP-1 and Insulin - GLP-1 and Glucagon - GLP-1 and GIP - GLP-1 and Gastrin/CCKB - GLP-1 and GLP-2 4. Corporate GLP-1 Receptor Agonist R&D Pipelines Companies Mentioned - Addex Pharmaceuticals - Amylin Pharmaceuticals - Arisaph Pharmaceuticals - Arisgen - Ascendis Pharma (Complex Biosystems) - Bio-ker - Biocompatibles International - ConjuChem - Dong-A Pharmaceutical - Eli Lilly - Emisphere Technologies - Faust Pharmaceuticals - GlaxoSmithKline - Hanmi Pharmaceuticals - Ipse - Mannkind - MDRNA (ex Nastech Pharmaceuticals) - Modigene - Novo Nordisk - OctoPlus - Oramed Pharmaceuticals - Pfizer - Proxima Concepts - Roche (& Chugai) - Rose Pharmaceuticals (ex Gastrotech) - Sanofi-Aventis - Teijin - Transition Therapeutics - TransTech Pharma - Unigene For more information visit http://www.researchandmarkets.com/research/7d4zkt/competitor
NVO: 55.94 (+1.34), ORMP: 6.23 (+0.06), TTHI: 6.99 (+0.08), LLY: 73.92 (+1.56), GSK: 48.23 (+0.51)

Emisphere Technologies, Inc. Announces Financial Results for Quarter Ended June 30, 2014
GlobeNewswire - Thu Aug 14, 7:00AM CDT
Emisphere Technologies, Inc. (OTCBB:EMIS) ("Emisphere" or the "Company"

today announced its financial results for the quarter ended June 30, 2014. The Company will host a conference call on Thursday, August 14, at 8:30 AM ET to discuss these results.

Emisphere Technologies, Inc. Announces Second Quarter 2014 Earnings Conference Call
GlobeNewswire - Wed Aug 13, 12:11PM CDT
Emisphere Technologies, Inc. (OTCQB:EMIS) (the "Company"

announced today that Management will host a conference call to discuss the Company's financial and operational results for the three months ended June 30, 2014 on Thursday, August 14, 2014 at 8:30 AM ET. A press release will be issued prior to market opening.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Digital Wine Atlas Maps 4.3 Million Vineyards Globally

Revolutionizing Viticulture with Data In today's wild world, climate change isn't just shifting weather patterns—it's upending the age-old map of wine-making regions. We've got a new player on the field: the World Winery Map. It's digital, massive, and it’s shaking things up for winemakers and grape enthusiasts alike. This platform covers a staggering 4.3 million...

ETERC's Ele Aims to Revolutionize STEM Education for All

The AI Mentor Battleground in Education Ever found yourself wondering how public schools could step up their game without dumping money down the tech rabbit hole? ETERC’s latest push with Ele may just be a game-changer for them. We're not talking about your run-of-the-mill chatbot regurgitating facts from the internet—this is an AI tricked out for personalized...

Bascom's Strategic Play on a Dallas Apartment Deal

Unpacking Bascom's Jasmine Acquisition In a market that's been more slippery than a greased pig, Bascom Group's move buying up Jasmine Apartments is capturing some eyes. Situated in North Dallas, this 370-unit complex ain't just another brick in the wall—it's Bascom's 42nd entry into Texas, reinforcing their knack for sniffing out deals others might tiptoe around,...

Wounded Warrior Project Honors Veterans at Gala Dinner

Wounded Warriors Gala: A Night of Heroic Honors In the swirling hum of Washington's gala scene, the Wounded Warrior Project (WWP) cuts through the noise with a sharp and poignant reminder of patriotism and community support. Their Courage Awards & Benefit Dinner®, pumped with the gravitas of corporate backing from the likes of Goldman Sachs, showcased a heartfelt...

Debbie's Dream Foundation Launches 2026 Youth Art Contest

Young Artists Called to Inspire a Cancer-Free World What's the first image that pops into your head when you think of a world free from cancer? That's the magic question on deck for this year's Youth Art Contest by Debbie's Dream Foundation. Imaginations are set to run wild as the competition opens its gates to artists under 18, calling for visions splashed across...

Sierra Ridge Advisors Join Gateway Financial Milestone

Big Moves in the Financial Advisory World Let's dive right in. Here's a real shakeup in the advisory realm: 28 financial advisors and team members from Sierra Ridge Advisor Group are packing their bags for Gateway Financial Partners. We're talking about a significant shift involving $825 million in assets under advisement. Instead of sticking with Sierra Ridge as it...

Debt Crisis Looms: Social Security at Risk

Debt Reality: A National Concern with Global Implications When it comes to the U.S. federal debt situation, the latest report from the National Seniors Policy Center is lighting a fire like no other, warning us that we're not crying wolf here. We've got fiscal numbers that may not sit well at breakfast. With roughly 67 cents of every new buck Uncle Sam borrows going to...

IRS Views Challenge Tax-Engineered Healthcare Schemes

Nonprofit Models Shine Amid IRS Scrutiny Out in Oxnard, California, there's a brewing storm in the healthcare sector. No, it's not a billing error or yet another scandal. We're talking about a seismic shift that could poke holes in those tax-engineered Section 105(b) programs, all thanks to some hard-hitting IRS memoranda. The Nonprofit–TPA Model: A Safer Bet? Enter...

Celebrate National Service Dog Month with Canine Companions

A Month to Celebrate Unseen Heroes Take a pause. We're talking about National Service Dog Month. What in the world could be more endearing than a pack of puppies, those hopeful bundles of joy, destined to grow up and play pivotal roles in people's lives? Canine Companions is rolling out the red carpet for these future heroes, with a nine-day Puppy Cam event from September...

Vetology Reinvents AI Models for Veterinary Radiology

Revamping AI in Veterinary Practices Out there in San Diego, Vetology's been rolling up its sleeves and getting down to brass tacks with a complete do-over of their AI classifiers. They’ve rebuilt all 94 of them, every last one, on a brand-new architecture. No small task, this overhaul stretched from June to August and it wasn't just paint and polish but a whole new...